Key Insights

Highlights

Treatment Research

12 treatments under study, led by Resection

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Active Not Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04539808Phase 2Active Not Recruiting

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Resection1
  • Leucovorin Calcium1
  • Diagnostic Imaging1
  • Losartan Potassium1
  • Gemcitabine1

Active Sponsors

  • Oregon Health and Science University1
  • OHSU Knight Cancer Institute1

Top Investigators

Related Conditions

  • Pancreatic Adenocarcinoma1
  • Stage 0 Pancreatic Cancer American Joint Committee On Cancer V81
  • Stage Iv Pancreatic Cancer American Joint Committee On Cancer V81
  • Stage Iii Pancreatic Cancer American Joint Committee On Cancer V81

Activity Timeline